Moderna Inc. completed the real-time review process needed for a full approval for the company’s Covid-19 vaccine in people aged 18 years and older.
Some 25 percent of SARS-CoV-2 infections among Los Angeles County residents occurred in fully vaccinated residents from May through July 25, a period that includes the impact of the highly transmissible Delta variant, U.S. officials reported on Aug. 24.
Theravance announced that the diversified biopharmaceutical company’s oral drug candidate for the possible treatment of ulcerative colitis failed to meet the primary endpoint of a Phase IIb study.
With COVID-19 infections on the rise in the United States as a result of the Delta variant, FCB Health New York (an IPG Health company) and GMHC have teamed up to help get LGBTQ+ individuals vaccinated and to shut down the misinformation brewing on social media with a new social campaign called “Ms. Information.”
Real Chemistry, a global health innovation company, and Aktana, a leader in intelligent customer engagement for the global life sciences industry, announced a partnership that will transform commercial strategy, engagement and execution.
Novartis said the company’s Kymriah CAR-T therapy did not meet the drug’s primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.
A third dose of Pfizer’s Covid-19 vaccine significantly improved protection from infection and serious illness among people aged 60 and older in Israel compared with those who received two shots, findings published by the Health Ministry showed on Aug. 22.
Health officials are looking into Canadian data that suggests the risk of heart inflammation after Moderna’s Covid-19 shot is occurring at higher rates in younger adults than previously believed.
Trial data from AstraZeneca on Aug. 20 raised the prospect of a new treatment to prevent Covid-19 beyond vaccines, giving hope in particular for people who respond poorly to immunization shots.
The UK drug regulator approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, as the nation battles rising hospitalizations due to the more infectious Delta variant.
